Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Bedaya Hospital

Status and phase: Not yet enrolling; Phase 2

Conditions: Infertility

Treatments: Drug: GnRH antagonist; Drug: Progestin primed ovarian stimulation

Study type: Interventional

Funder types: Other

Identifiers

NCT06212102

Double stimulation

Details and patient eligibility

About

The aim of this randomized controlled trial was to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.

Enrollment: 120 estimated patients

Sex: Female

Ages: 35 to 44 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients belonging to Poseidon group 4

Exclusion criteria

• PCOS
• Endometriosis
• History of recurrent abortion

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

120 participants in 2 patient groups

Progestin primed ovarian stimulation group

Experimental group

Description:

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS. In subsequent cycle, frozen embryo transfer was done

Treatment:

Drug: Progestin primed ovarian stimulation

GnRH antagonist group

Active Comparator group

Description:

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS. In subsequent cycle, frozen embryo transfer was done

Treatment:

Drug: GnRH antagonist